SynthesisFrontiers in nutrition2026
Mediterranean diet with high-phenolic EVOO slows kidney function decline and reduces inflammation in nondialysis CKD: a meta-analysis.
Synthesis in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The Role of Diet and Gut Microbiome in CKD Progression and Therapy.Journal of clinical medicine · 2026Review
- Review
- Association of heavy metal mixtures with liver function biomarkers: multi-model analysis identifies cadmium as the primary driver.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Evidence regarding the renoprotective effect of the Mediterranean diet (MedDiet) in patients with nondialysis chronic kidney disease (CKD) remains inconsistent. This may be partly attributed to variability in the phenolic content of extra virgin olive oil (EVOO), a key bioactive component. Methods: We conducted a systematic review and meta-analysis to quantify the effect of the MedDiet on renal and cardiometabolic outcomes in adults with nondialysis CKD and to explore the role of high-phenolic EVOO as a potential effect modifier. We searched multiple databases for interventional and observational studies comparing a MedDiet to control diets in adults with CKD stages 1-5. Random-effects meta-analyses were performed. Results: Ten studies involving 1,073 participants were included. The MedDiet was associated with a modest improvement in estimated glomerular filtration rate (eGFR) (mean difference 2.44 mL/min/1.73 m Conclusion: In patients with mild-to-moderate CKD, the MedDiet may slow kidney function decline. The benefits appear to be mediated through complementary pathways: renal protection from the overall dietary pattern and a specific anti-inflammatory effect attributable to high-phenolic EVOO. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251124826, identifier PROSPERO (CRD420251124826).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.